Ironwood Pharmaceuticals Inc
NASDAQ:IRWD
Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc. is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. The company is headquartered in Boston, Massachusetts and currently employs 219 full-time employees. The company went IPO on 2010-02-03. The company operates in the human therapeutics business segment. Its product candidate LINZESS (linaclotide) is available to adult men and women suffering from IBS-C or CIC in the United States, and Mexico and to adult men and women suffering from IBS-C. Its linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries. The Company’s products pipeline includes IW-3300, which is a GC-C agonist, for the potential treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis, and CNP-104 is a tolerizing immune modifying nanoparticle.
Ironwood Pharmaceuticals, Inc. is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. The company is headquartered in Boston, Massachusetts and currently employs 219 full-time employees. The company went IPO on 2010-02-03. The company operates in the human therapeutics business segment. Its product candidate LINZESS (linaclotide) is available to adult men and women suffering from IBS-C or CIC in the United States, and Mexico and to adult men and women suffering from IBS-C. Its linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries. The Company’s products pipeline includes IW-3300, which is a GC-C agonist, for the potential treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis, and CNP-104 is a tolerizing immune modifying nanoparticle.
LINZESS Performance: LINZESS U.S. net sales were $865 million in 2025, meeting guidance, with 11% demand growth and 8% new-to-brand growth year-over-year.
New Pediatric Approval: LINZESS received FDA approval for use in IBS-C patients aged 7 and older, making it the only prescription drug approved for this group.
2026 Outlook: Management expects LINZESS U.S. net sales to exceed $1.1 billion in 2026, a more than 30% increase, driven by improved net price and low single-digit demand growth.
Apraglutide Progress: Apraglutide’s confirmatory Phase III trial (STARS-2) will begin site activation in Q2 2026, aiming for a future NDA submission before the end of 2029.
Financial Strength: 2025 adjusted EBITDA was $138 million, with $250 million in cash and cash equivalents at year-end, and a commitment to reduce debt below $300 million in 2026.
Expense Management: Operating expenses were reduced by $61 million year-over-year, resulting in $127 million in cash flow from operations.
Strategic Alternatives: Management emphasized their improved financial position and openness to options enhancing shareholder value, but stressed confidence in their stand-alone prospects.
